Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: A multireader diagnostic performance study

Radiology

Volumn 273, Issue 3, 2014, Pages 813-820

  Mileto, Achille ^a,b   Marin, Daniele ^a   Alfaro Cordoba, Marcela ^c   Ramirez Giraldo, Juan Carlos ^d   Eusemann, Christian D ^d   Scribano, Emanuele ^b   Blandino, Alfredo ^b   Mazziotti, Silvio ^b   Ascenti, Giorgio ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; IOMEPROL; CONTRAST MEDIUM; IOPAMIDOL;

ADULT; AGED; ARTICLE; CANCER GRADING; COMPUTED TOMOGRAPHY SCANNER; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PAPILLARY CARCINOMA; PAPILLARY RENAL CELL CARCINOMA; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; KIDNEY NEOPLASMS; MIDDLE AGED; NEPHRECTOMY; PATHOLOGY; RADIOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IOPAMIDOL; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHRECTOMY; RETROSPECTIVE STUDIES;

EID: 84916608502     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140171     Document Type: Article

References (33)

1. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011;261(1):165-171
2. Figueiras RG, Padhani AR, Goh VJ, et al. Novel oncologic drugs: what they do and how they affect images. RadioGraphics 2011;31(7):2059-2091
3. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007;370(9605):2071-2073
4. Chandarana H, Rosenkrantz AB, Mussi TC, et al. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology 2012;265(3):790-798
5. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183(2):131-133
6. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011;104(3):399-406
7. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-2490
8. Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Raman SS. Clear cell renal cell carcinoma: Discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology 2013;267(2):444-453
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-134
10. Powles T, Chowdhury S, Jones R, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011;104(5): 741-745
11. Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther 2009;9(3):373-379
12. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011;258(1):41-56
13. Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: Differentiation with CT. Radiology 2007;244(2):494-504
14. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol 2002;178(6):1499-1506
15. Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 2002;178(2):367-372
16. Ruppert-Kohlmayr AJ, Uggowitzer M, Meissnitzer T, Ruppert G. Differentiation of renal clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement parameters. AJR Am J Roentgenol 2004;183(5):1387-1391
17. Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: Dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes-correlation with pathologic findings. Radiology 2009;250(3):793-802
18. Pandharipande PV, Gervais DA, Hartman RI, et al. Renal mass biopsy to guide treatment decisions for small incidental renal tumors: A cost-effectiveness analysis. Radiology 2010;256(3):836-846
19. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 1995;13(4):254-261
20. Leveridge MJ, Finelli A, Kachura JR, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 2011;60(3):578-584
21. Ascenti G, Mileto A, Krauss B, et al. Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: Iodine quantification versus standard enhancement measurements. Eur Radiol 2013;23(8):2288-2295
22. Mileto A, Marin D, Nelson RC, Ascenti G, Boll DT. Dual energy MDCT assessment of renal lesions: An overview. Eur Radiol 2014;24(2): 353-362
23. Chandarana H, Megibow AJ, Cohen BA, et al. Iodine quantification with dual-energy CT: Phantom study and preliminary experience with renal masses. AJR Am J Roentgenol 2011;196(6):W693-W700
24. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Radiology 2003;226(1):24-28
25. Ascenti G, Mazziotti S, Lamberto S, et al. Dual-energy CT for detection of endoleaks after endovascular abdominal aneurysm repair: usefulness of colored iodine overlay. AJR Am J Roentgenol 2011;196(6):1408-1414
26. Graser A, Johnson TR, Hecht EM, et al. Dual- energy CT in patients suspected of having renal masses: Can virtual nonenhanced images replace true nonenhanced images? Radiology 2009;252(2):433-440
27. Ascenti G, Mazziotti S, Mileto A, et al. Dual-source dual-energy CT evaluation of complex cystic renal masses. AJR Am J Roentgenol 2012;199(5):1026-1034
28. Ascenti G, Mileto A, Gaeta M, Blandino A, Mazziotti S, Scribano E. Single-phase dualenergy CT urography in the evaluation of haematuria. Clin Radiol 2013;68(2):e87-e94
29. Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: An ex vivo study. Am J Surg Pathol 2011;35(7):949-961
30. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-663
31. Kressel HY. Beyond the impact factor: Enhancing the impact of imaging research published in Radiology. Radiology 2014;270(1):3-6
32. Ochodo EA, de Haan MC, Reitsma JB, Hooft L, Bossuyt PM, Leeflang MM. Overinterpretation and misreporting of diagnostic accuracy studies: Evidence of "spin". Radiology 2013;267(2):581-588
33. Kaza RK, Caoili EM, Cohan RH, Platt JF. Distinguishing enhancing from nonenhancing renal lesions with fast kilovoltageswitching dual-energy CT. AJR Am J Roentgenol 2011;197(6):1375-1381.